TOKYO and CAMBRIDGE, Mass., July 15, 2026 – (JCN Newswire) – Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application(sBLA) for a once-weekly lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI IQLIK®) as an initiation dose for the treatment of early Alzheimer’s disease.LEQEMBI IQLIK is administered via an autoinjector…
Read More
